KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Fiche du document
2008
- doi: 10.1007/s00428-008-0665-y
- issn: 0945-6317
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00428-008-0665-y
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/18802721
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0945-6317
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C9BB6B74850A7
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
TherapyCiter ce document
J.H. van Krieken et al., « KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. », Serveur académique Lausannois, ID : 10.1007/s00428-008-0665-y
Métriques
Partage / Export
Résumé
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.